<DOC>
	<DOCNO>NCT03064282</DOCNO>
	<brief_summary>Treatment patient prostatic hyperplasia topical papaverine .</brief_summary>
	<brief_title>Prostatic Hyperplasia Treatment Cancer Prevention</brief_title>
	<detailed_description>Patients obstructive void high PSA study regression symptom decline PSA .</detailed_description>
	<mesh_term>Hyperplasia</mesh_term>
	<mesh_term>Prostatic Hyperplasia</mesh_term>
	<mesh_term>Papaverine</mesh_term>
	<criteria>patient symptom e.g . obstructive voiding , hyperplasia high PSA patient chemotherapy abnormal lab value e.g . liver function , GFR CAD</criteria>
	<gender>Male</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>March 2017</verification_date>
</DOC>